Could a pill make radiation work better for sarcoma patients?

NCT ID NCT05938374

Completed Disease control Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tested whether adding the drug fluzoparib to standard preoperative radiation therapy improves outcomes for people with soft tissue sarcoma in the arms, legs, or trunk. Fifty-two adults took part, receiving either radiation alone or radiation plus fluzoparib before surgery. The study looked at wound complications, side effects, and quality of life after treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Fluzoparib (a PARP inhibitor drug taken orally)
What this could lead to: If successful, this could lead to a new treatment option that improves tumor control and reduces wound complications after surgery for soft tissue sarcoma.
What could go wrong: This is a small, early-phase trial with only 52 participants, so results may not apply broadly. Adding fluzoparib to radiation may increase side effects like fatigue or bone marrow suppression.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SOFT TISSUE SARCOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

sarcoma soft tissue sarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SOFT TISSUE SARCOMA

Contacts and locations

Locations

Beijing Jishuitan Hospital

Beijing, Beijing Municipality, China
Cancer Hospital and Institute, National Cancer Center, Chinese Academy of Medical Sciences & Peking Union Medical Center

Beijing, Beijing Municipality, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.